Id: acc0705
Group: 1sens
Protein: beta-catenin
Gene Symbol: CTNNB1
Protein Id: P35222
Protein Name: CTNB1_HUMAN
PTM: ubiquitination
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Pancreas Cancer
Disease Subtype: PDAC
Disease Cellline: MIA PaCa-2
Disease Info:
Drug: niclosamide + gemcitabine
Drug Info: "Niclosamide is an anthelmintic drug used to treat tapeworm infections by inhibiting mitochondrial oxidative phosphorylation in parasites. Gemcitabine is a nucleoside analog antimetabolite chemotherapy agent that inhibits DNA synthesis and is used to treat various solid tumors including non-small cell lung cancer, pancreatic cancer, and breast cancer."
Effect: modulate
Effect Info: The combination therapy of nikethamide and gemcitabine inhibits the proliferation and apoptosis of pancreatic cancer cells by inducing the ubiquitination of beta-catenin.
Note: drug comb
Score: 4.0
Pubmed(PMID): 37917550
Sentence Index:
Sentence:

Sequence & Structure:

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Withdrawn colorectal adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Recruiting cirrhosis of liver ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed chronic myelogenous leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Terminated neoplasm ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic carcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed Malignant Pancreatic Neoplasm ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - A Prostate cancer Ubiquitination 30532005
- - D Colorectal cancer Ubiquitination 29789528
- - D Gastric cancer Ubiquitination 31747856
- - D Cancer Ubiquitination 30714168
- - P Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 24088787
- - P Epithelial ovarian cancer Ubiquitination 37186433
- - P Gastric cancer Ubiquitination 33159601
- - P Colorectal cancer Ubiquitination 31527801
- - U Hepatocellular carcinoma Ubiquitination 35568970
- - U Prostate cancer Ubiquitination 35637955
- - U Hepatocellular carcinoma Ubiquitination 29189991
- - U Renal cell carcinoma Ubiquitination 31926310
- - U Colorectal cancer Ubiquitination 37424824
- - U Lung cancer Ubiquitination 37726816
- - U Pancreatic cancer Ubiquitination 34325342
- - U Colorectal cancer Acetylation 29563608
- - U Papillary thyroid carcinoma Phosphorylation 35350839
- - U Non-small cell lung cancer Phosphorylation 35986102
- - U Triple-negative breast cancer Phosphorylation 33407765

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: